Evidence map›Paper›PMID 35941717›Full record

ArticleGlobal public health2022

Challenges and best practices for hepatitis C care among people who inject drugs in resource limited settings: focus group discussions with healthcare providers in Kenya.

Rie Seu, Lindsey R Riback, Mercy Nyakowa, John Lizcano, Helgar Musyoki, Jonathan Ross, Peter Cherutich, Ann E Kurth, Matthew J Akiyama

Open access · greenAbstract read
In one paragraph

Article in Global public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Advancing Hepatitis C Elimination in Africa: Insights from Egypt.Hepatic medicine : evidence and research · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Rie SeuAlbert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Lindsey R RibackAlbert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Mercy NyakowaKenya Ministry of Health, National AIDS & STI Control Program (NASCOP), Nairobi, Kenya.
John LizcanoYale University School of Nursing, Orange, CT, USA.
Helgar MusyokiKenya Ministry of Health, National AIDS & STI Control Program (NASCOP), Nairobi, Kenya.
Jonathan RossAlbert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.ORCID 0000-0001-6126-3048
Peter CherutichKenya Ministry of Health, National AIDS & STI Control Program (NASCOP), Nairobi, Kenya.
Ann E KurthYale University School of Nursing, Orange, CT, USA.ORCID 0000-0003-2300-6723
Matthew J AkiyamaAlbert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.ORCID 0000-0003-4290-3083
Albert Einstein College of Medicine · USMinistry of Health · KEYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Test and Linkage to Care (TLC_IDU) KenyaR01DA032080 · NIDA · YALE UNIVERSITY · PI CHERUTICH, PETER KIPKOECH, KURTH, ANN ELIZABETH · 2011 to 2015
$4.1M
Leveraging HCV Phylogenetic Networks to Prevent HIV and Other Blood Borne Infections Among People Who Inject DrugsDP2DA053730 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI AKIYAMA, MATTHEW · 2021 to 2021
$2.5M
Advance Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants LivingR00DA043011 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI AKIYAMA, MATTHEW · 2020 to 2022
$747k
NCATS NIH HHS UL1 TR001863NIDA NIH HHS DP2 DA053730NIDA NIH HHS R00 DA043011NIDA NIH HHS R01 DA032080
6 · The paper itself

Abstract

People who inject drugs (PWID) living with Hepatitis C (HCV) in low- and middle-income countries face substantial barriers to HCV care. We sought to gain healthcare providers' perspectives on challenges and best practices for HCV care provision among PWID in Kenya. We conducted three focus group discussions (FGD) with 23 healthcare providers working with PWID living with HCV in Nairobi and Mombasa. Transcribed interviews were analysed thematically. Overarching themes regarding HCV prevention and treatment were: (1) lack of HCV-related knowledge at the provider and patient levels; (2) stigmatisation of people living with HCV and PWID; and (3) difficulties among PWID with navigating the healthcare system. Some providers suggested systematically integrating HCV care into existing PWID-specific harm reduction programs to improve HCV care provision as well as creating national HCV guidelines to guide clinicians. This study highlights the need for national HCV treatment guidelines and increased public HCV education, as well as culturally sensitive models integrating HCV care into programs PWID are already accessing. These strategies will be useful in improving access to HCV care among PWID and has the potential to decrease HCV transmission and prevalence among this vulnerable population.

Indexed as

Drug UsersHepatitis CSubstance Abuse, IntravenousFocus GroupsHarm ReductionHepacivirusHumansKenyafocus group discussionHepatitis C virusinjection drug useKenyapeople who inject drugs

Identifiers

PMID35941717
PMCPMC9898079
OpenAlexW4292451979

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.